Literature DB >> 18164694

CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats.

Lissiana M V Aguiar1, Danielle S Macêdo, Silvania M M Vasconcelos, Aline A Oliveira, F Cléa F de Sousa, Glauce S B Viana.   

Abstract

The present work showed the effects of 8-(-3-chlorostyryl)-caffeine (CSC), an A(2A) receptors antagonist and MAO B inhibitor, on behavior and biochemical alterations in 6-OHDA-lesioned rats. Male Wistar rats (280 g) were injected with CSC (1 and 5 mg/kg, i.p.) alone or combined with l-DOPA (50 mg/kg+benserazide 12.5 mg/kg), starting 6 days after the striatal 6-OHDA lesions, and once daily for the next 7 days. Fourteen days after the 6-OHDA lesion (and 24 h after CSC or vehicle), the number of net body rotations/h (after the apomorphine challenge) was recorded and, at the next day, animals were sacrificed. The ipsilateral striatum was used for HPLC measurements of monoamines and amino acids or for determination of nitrite contents and lipid peroxidation. Results showed that the increase in body rotation, induced by the 6-OHDA lesion, after the apomorphine challenge, was significantly and dose-dependently reversed by CSC. Furthermore, the decreased striatal levels of DA and metabolites, in the 6-OHDA-lesioned rats, were reversed after CSC treatment, and these effects were potentiated after the combination with l-DOPA. Similar results were observed with NE, 5-HT and 5-HIAA. While glutamate and GABA were increased in the 6-OHDA-lesioned group, CSC alone or mainly combined with l-DOPA reversed these alterations. In addition, the CSC treatment of 6-OHDA-lesioned rats reversed the increased nitrite formation and lipid peroxidation induced by 6-OHDA. In conclusion, CSC by means of its dual action as A(2A) antagonist and MAO-B inhibitor reversed behavior and biochemical alterations, observed in the 6-OHDA-lesioned rats, pointing out to its potential benefit for the treatment of PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18164694     DOI: 10.1016/j.brainres.2007.11.051

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Dopamine depletion in either the dorsomedial or dorsolateral striatum impairs egocentric Cincinnati water maze performance while sparing allocentric Morris water maze learning.

Authors:  Amanda A Braun; Robyn M Amos-Kroohs; Arnold Gutierrez; Kerstin H Lundgren; Kim B Seroogy; Matthew R Skelton; Charles V Vorhees; Michael T Williams
Journal:  Neurobiol Learn Mem       Date:  2014-11-13       Impact factor: 2.877

2.  Metabolic changes detected by ex vivo high resolution 1H NMR spectroscopy in the striatum of 6-OHDA-induced Parkinson's rat.

Authors:  Hong-Chang Gao; Huan Zhu; Cai-Yong Song; Li Lin; Yun Xiang; Zhi-Han Yan; Guang-Hui Bai; Fa-Qing Ye; Xiao-Kun Li
Journal:  Mol Neurobiol       Date:  2012-08-31       Impact factor: 5.590

3.  Dorsal striatal dopamine depletion impairs both allocentric and egocentric navigation in rats.

Authors:  Amanda A Braun; Devon L Graham; Tori L Schaefer; Charles V Vorhees; Michael T Williams
Journal:  Neurobiol Learn Mem       Date:  2012-03-21       Impact factor: 2.877

4.  Effect of adenosine A(2A) receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum.

Authors:  Krystyna Gołembiowska; Anna Dziubina; Magdalena Kowalska; Katarzyna Kamińska
Journal:  Neurotox Res       Date:  2009-03-05       Impact factor: 3.911

5.  Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.

Authors:  Pablo Duarte; Antonio Cuadrado; Rafael León
Journal:  Handb Exp Pharmacol       Date:  2021

6.  Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.

Authors:  Krystyna Gołembiowska; Anna Dziubina
Journal:  Neurotox Res       Date:  2011-08-10       Impact factor: 3.911

Review 7.  Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease.

Authors:  Cristina Miguelez; Teresa Morera-Herreras; Maria Torrecilla; Jose A Ruiz-Ortega; Luisa Ugedo
Journal:  Front Neural Circuits       Date:  2014-03-17       Impact factor: 3.492

Review 8.  Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson's Disease.

Authors:  Giovanni Schepici; Serena Silvestro; Placido Bramanti; Emanuela Mazzon
Journal:  Int J Mol Sci       Date:  2020-07-04       Impact factor: 5.923

Review 9.  Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches.

Authors:  Luiza R Nazario; Rosane S da Silva; Carla D Bonan
Journal:  Front Neurosci       Date:  2017-11-23       Impact factor: 4.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.